Business Wire

Meilleurtaux Accelerates AI Strategy as First Broker to Launch Mortgage Lending App on ChatGPT in France

29.5.2026 09:00:00 CEST | Business Wire | Press release

Share

Dedicated channel enables hundreds of millions of users to simulate their borrowing capacity and facilitate loan applications directly within ChatGPT’s interfaceNew milestone in “AI First” strategy gives French consumers greater control of their financial future.

Meilleurtaux, a leading omnichannel financial services brokerage platform (credit, insurance, investments), announced today the launch of a dedicated mortgage lending app directly within ChatGPT, OpenAI’s artificial intelligence platform, which now has several hundred million active users worldwide. With this new service, Meilleurtaux reaches another milestone in its “AI First” strategy and reinforces its commitment to supporting French consumers in the adoption of artificial intelligence.

Simulating a Mortgage in ChatGPT: Simple, Fast, No Forms Required

Until now, obtaining a borrowing capacity simulation meant browsing a website, filling out forms, and waiting for a response. Meilleurtaux has changed that: users can now run simulations directly within ChatGPT, using natural language, just like in a conversation.

In only a few exchanges, users receive:

  • a personalized borrowing capacity simulation using Meilleurtaux’s real-time rates;
  • an assessment of the feasibility of their property purchase;
  • the option to be contacted by a Meilleurtaux mortgage expert for a smoother, more personalized experience, or to submit their application directly on the website.

“With several hundred million active users, ChatGPT has become an essential digital destination. Our ambition is to be present wherever our customers are, offering them immediate, clear, and personalized access to the best financial information. That is what giving French consumers the freedom to choose really means: concretely removing obstacles, simplifying processes, and making Meilleurtaux expertise available through a simple conversation while also enabling our advisors to focus on personal support and guidance where it makes the biggest impact for customers.”
Thomas Vandeville, CEO of Meilleurtaux

A New Milestone in Meilleurtaux’s “AI First” Strategy

This initiative is part of the Meilleurtaux Group’s accelerating “AI First” roadmap, which aims to double the company’s size within three years. We envisage AI playing a central role at Meilleurtaux Group – enhancing the customer experience through the journey, empowering our personal advisors to give the best hands-on service at the key moments that matter, and bringing the collective assets of the Group in support of each business line (across credit, insurance and investments). This ChatGPT milestone builds on deployments already underway, such as in back-office automation and customer engagement through Salesforce’s Agentforce platform at Meilleurtaux Placement, further demonstrating the consistency of a group-wide strategy.

This integration is powered by the MCP (Model Context Protocol), which enables ChatGPT’s conversational capabilities to connect in real time with Meilleurtaux’s proprietary data and tools, providing direct access to offers from 125 partners.

“The MCP protocol enabled us to connect ChatGPT to our real-time data in just under two months. For us, AI is no longer a transformation project, it is now an operating model. At Meilleurtaux, we are industrializing our use cases at an accelerating pace, and ChatGPT is only one step among many others.”
Adrien Vesteghem, Chief Data & AI Officer at Meilleurtaux

About Meilleurtaux

Founded in 1999, the Meilleurtaux Group has become the leading French omnichannel brokerage platform across all financial services (investments, insurance, and lending), serving both individuals and professionals. In an increasingly complex financial environment, faced with a multitude of offers that are often difficult to decipher, Meilleurtaux combines the expertise of its teams with the power of its technology to identify the most cost-effective, high-performing, and tailored solutions for each client’s specific needs. Remaining true to its values of transparency, impartiality, and proximity, the Group supports its clients at every stage of their projects, providing simple and clear access to the best financial and insurance information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529451810/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye